Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31047861 | 1.00 | AAK1 (0.48) | AAK1NPC1RECQLRAB9ASMN1; SMN2 | |
| SCHEMBL506329 | 0.86 | AAK1 (0.50) | AAK1AKR1B1P2RX7AKR1A1BDKRB1 | |
| SCHEMBL4090969 | 0.83 | EGFR (0.45) | AAK1NPC1RECQLRAB9ASMN1; SMN2 | |
| SCHEMBL31047882 | 0.83 | AAK1 (0.47) | AAK1NPC1RECQLRAB9ASMN1; SMN2 | |
| SCHEMBL31047823 | 0.82 | AAK1 (0.43) | AAK1NPC1RECQLRAB9ASMN1; SMN2 | |
| SCHEMBL25416693 | 0.82 | APLNR (0.41) | AAK1GAA | |
| SCHEMBL15145787 | 0.81 | P2RX7 (0.49) | AAK1AKR1B1P2RX7AKR1A1BDKRB1 | |
| SCHEMBL6232571 | 0.81 | RIPK1 (0.50) | NPC1RAB9AMAPTGAA | |
| SCHEMBL31047887 | 0.81 | AAK1 (0.41) | AAK1NPC1RECQLRAB9ASMN1; SMN2 | |
| SCHEMBL2552330 | 0.79 | AAK1 (0.50) | AAK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9873696-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873696-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170217959-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-08-03 | — | — | US | disclosed |
| US-20170217959-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-08-03 | — | — | US | disclosed |
| US-9555041-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-01-31 | — | — | US | disclosed |
| US-9555041-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-01-31 | — | — | US | disclosed |
| US-20160184316-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160184316-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-06-30 | — | — | US | disclosed |
| US-9120758-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-09-01 | — | — | US | disclosed |
| US-9120758-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-09-01 | — | — | US | disclosed |
| EP-2651900-B1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R & D IP LLC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-20140011997-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2014-01-09 | — | — | US | disclosed |
| US-20140011997-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2014-01-09 | — | — | US | disclosed |
| US-8563512-B2 | Neprilysin inhibitors | THERAVANCE, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-8563512-B2 | Neprilysin inhibitors | THERAVANCE, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-20120157386-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157386-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2012082857-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011997-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | AAK1 2570/4885NPC1 194/4885RECQL 1203/4885 |
| US-20160184316-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | AAK1 2570/4885NPC1 194/4885RECQL 1203/4885 |
| US-20120157386-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | AAK1 2570/4885NPC1 194/4885RECQL 1203/4885 |
| US-20170217959-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | AAK1 2570/4885NPC1 194/4885RECQL 1203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.